Coumermycin A1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Coumermycin A1
- Accession Number
- DB13912
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Coumermycin A1 (DB13912)
- Weight
- Average: 1110.092
Monoisotopic: 1109.37533932 - Chemical Formula
- C55H59N5O20
- Synonyms
- Coumamycin
- Coumermycin
- Notomycin A1
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Coumermycin A1. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Coumermycin A1. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Coumermycin A1. Dexmethylphenidate The serum concentration of the active metabolites of Coumermycin A1 can be increased when Coumermycin A1 is used in combination with Dexmethylphenidate. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Coumermycin A1. Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Coumermycin A1. Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Coumermycin A1. Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Coumermycin A1. Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Coumermycin A1. Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Coumermycin A1. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as coumarin glycosides. These are aromatic compounds containing a carbohydrate moiety glycosidically bound to a coumarin moiety.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- Sub Class
- Coumarin glycosides
- Direct Parent
- Coumarin glycosides
- Alternative Parents
- Phenolic glycosides / 4-hydroxycoumarins / O-glycosyl compounds / 1-benzopyrans / 2-heteroaryl carboxamides / Pyrrole carboxamides / Pyranones and derivatives / Substituted pyrroles / Benzenoids / Dicarboxylic acids and derivatives show 17 more
- Substituents
- 1-benzopyran / 2-heteroaryl carboxamide / 4-hydroxycoumarin / Acetal / Alcohol / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzopyran / Carboxamide group show 36 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- PCH9QZ1IIH
- CAS number
- 4434-05-3
- InChI Key
- WTIJXIZOODAMJT-IYKSDEDASA-N
- InChI
- InChI=1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m0/s1
- IUPAC Name
- (3S,4R,5S,6S)-5-hydroxy-6-[(4-hydroxy-3-{5-[(4-hydroxy-7-{[(2S,3S,4R,5S)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyloxy)oxan-2-yl]oxy}-8-methyl-2-oxo-2H-chromen-3-yl)carbamoyl]-4-methyl-1H-pyrrole-3-amido}-8-methyl-2-oxo-2H-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyloxan-4-yl 5-methyl-1H-pyrrole-2-carboxylate
- SMILES
- CO[[email protected]]1[[email protected]](OC(=O)C2=CC=C(C)N2)[[email protected]](O)[[email protected]@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=C(C)C(=CN2)C(=O)NC2=C(O)C4=C(OC2=O)C(C)=C(O[[email protected]]2OC(C)(C)[[email protected]@H](OC)[[email protected]](OC(=O)C5=CC=C(C)N5)[[email protected]@H]2O)C=C4)C(=O)O3)OC1(C)C
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54697785
- PubChem Substance
- 347829332
- ChemSpider
- 23287305
- BindingDB
- 50048490
- ChEMBL
- CHEMBL389471
- Wikipedia
- Coumermycin_A1
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0111 mg/mL ALOGPS logP 4.59 ALOGPS logP 4.39 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 5.21 ChemAxon pKa (Strongest Basic) -4 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 16 ChemAxon Hydrogen Donor Count 9 ChemAxon Polar Surface Area 347.07 Å2 ChemAxon Rotatable Bond Count 16 ChemAxon Refractivity 281.22 m3·mol-1 ChemAxon Polarizability 115.95 Å3 ChemAxon Number of Rings 9 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on September 22, 2017 09:49 / Updated on June 12, 2020 10:53
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates